Introduction
============

Colorectal cancer (CRC) is one of the most frequently diagnosed cancers of the digestive system. It was estimated that there would be 97,220 new cases and 50,630 CRC-related deaths in the United States in 2018 ([@b1-ol-0-0-10605]). Much of the rising burden is attributable to population growth and aging, as well as sociodemographic changes. Recurrence is the major cause of CRC-related death ([@b2-ol-0-0-10605]).

Despite the diagnosis and treatment of CRC, the survival of the patient is closely associated to the stage of the tumor at diagnosis, and 40--50% of patient mortality is due to distant metastasis ([@b3-ol-0-0-10605],[@b4-ol-0-0-10605]). Considering the enormous threat of CRC to human health, new diagnostic and therapeutic approaches are required for early cancer detection and effective treatment ([@b5-ol-0-0-10605]).

In order to find a more effective treatment for CRC, a more thorough understanding of its pathogenesis is important. Previously, there has been increasing evidence that microRNAs (miRNAs) are functional in cancer progression by downregulating their targets, including mRNA, long non-coding RNA (lncRNA), circular RNA and pseudogenes ([@b6-ol-0-0-10605]--[@b8-ol-0-0-10605]). Nevertheless, overexpression of these targets could abolish the downregulatory effect of miRNA in turn ([@b9-ol-0-0-10605]--[@b11-ol-0-0-10605]). Moreover, more than one miRNA target could compete with miRNAs as competing endogenous RNA (ceRNA) and overexpression of one ceRNA could indirectly upregulate other ceRNAs ([@b12-ol-0-0-10605],[@b13-ol-0-0-10605]).

ceRNA crosstalk was first proposed by Poliseno *et al* ([@b14-ol-0-0-10605]). Phosphatase and tensin homolog pseudogene 1 (PTENP1) could upregulate PTEN by sponging their common miRNAs. It was subsequently confirmed that various genes could participate in the development of cancer through ceRNA mechanisms ([@b15-ol-0-0-10605]). In breast cancer, overexpression of NEAT1 induced by BRCA1-deficiency can silence hsa-miR-129-5p and upregulate WNT4, a target of hsa-miR-129-5p, which leads to activation of oncogenic WNT signaling ([@b16-ol-0-0-10605]). Liang *et al* ([@b17-ol-0-0-10605]) reported that the oncogenic functions of lncRNA H19 in CRC may be attributed to its ceRNA activity to sequester miR-138 and miR-200a and therefore, upregulate the expression levels of VIM, ZEB1 and ZEB2, the critical genes involved in epithelial mesenchymal transition. With the development of gene sequencing technology, it has been shown that the expression of various lncRNAs is either upregulated or downregulated in CRC tissues to regulate several signaling pathways, such as the Wnt, p13K/Akt and Ras pathways, through ceRNA crosstalk ([@b18-ol-0-0-10605],[@b19-ol-0-0-10605]). Therefore, it has been proven that ceRNA crosstalk is a critical mechanism for the complex pathogenesis and multi-step development of CRC, which may be a potential starting point for the development of novel CRC treatment methods, which deserves further study. The aim of the present study, was to identify a ceRNA network between non-coding RNAs and coding genes in CRC and to reveal the potential mechanism of CRC progression, which may aid in establishing a novel clinical CRC treatment system.

Materials and methods
=====================

### Gene datasets and clinical information

Raw gene expression data of the GSE109454 ([@b20-ol-0-0-10605]) and GSE41655 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE41655>) datasets were downloaded from the National Center of Biotechnology Information Gene Expression Omnibus (GEO) database (<https://www.ncbi.nlm.nih.gov/gds/>). In the GSE109454 dataset, tumor samples and adjacent non-tumor samples were obtained from 6 patients with CRC. Clinical information of these CRC patients from the original study is shown in [Table I](#tI-ol-0-0-10605){ref-type="table"}. In the GSE41655 dataset, there were 15 normal colorectal samples, 59 colorectal adenoma samples and 33 colorectal adenocarcinoma samples. Clinical information of these 107 cases from the original study is shown in [Table II](#tII-ol-0-0-10605){ref-type="table"}. Histological tumor type and grade were evaluated according to the World Health Organization cancer classification ([@b21-ol-0-0-10605]) and tumor stage according to the Union for International Cancer Control TNM classification ([@b22-ol-0-0-10605]).

### Identification of differentially expressed genes (DEGs)

GEO2R (<http://www.ncbi.nlm.nih.gov/geo/geo2r/>) is an online tool provided by GEO. GEO2R is based on the R language limma package (v3.26.8) ([@b23-ol-0-0-10605]). GEO2R was used to screen DEGs between tumor and normal samples in the GSE41655 and GSE109454 datasets. At the same time, using false discovery rate correction, multiple t-tests were used to determine the statistical significance of the DEGs. \|log~2~ fold change (FC)\|\>1 and a P-value \<0.05 were set as the cut-off criteria. Subsequently, probes without a corresponding gene symbol were filtered.

### Weighted gene co-repression analysis (WGCNA)

To screen significant co-expression modules, WGCNA was performed as previously described ([@b24-ol-0-0-10605],[@b25-ol-0-0-10605]). Probe sets were first filtered based on the variance of expression value across all samples. Probe sets with repeating gene symbols were also removed based on the expression variance. The R package WGCNA (v1.61) ([@b26-ol-0-0-10605]) was used to construct the co-expression networks. Independent signed networks were constructed from the CRC samples and normal samples. The adjacency matrix was constructed using a soft threshold power of 12 to make the soft threshold \>0.8. Network interconnectedness was measured by calculating the topology overlap using the TOMdist function with a signed TOM-Type. The average hierarchical clustering was performed to group the genes based on the topological overlap dissimilarity measure (1-TOM) of their connection strengths. The network modules were identified using a dynamic tree cut algorithm, with a minimum cluster size of 30 and a merge threshold function of 0.25. Genes that were not assigned to particular modules were designated as grey. The module that had the strongest association with CRC was selected for further analysis and the co-expression in this module was filtered as follows: i) The weight score of co-expression \>0.3; ii) only the coding and non-coding co-expression relationships were retained; iii) only the genes that were differentially expressed were retained; and iv) only the genes in one pair that had the same expression tendency were retained.

### Gene function analysis

To determine the function of the selected genes in CRC, Gene Ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis for the genes in the co-expression network were implemented using DAVID (v6.8; <http://david.ncifcrf.gov/>). In the present study, pathway and process enrichment analysis was performed using the following ontological sources: GO Biological Processes (BPs) and KEGG Pathway. All genes in the *H. sapiens* genome were used as background in the enrichment analysis. The P-value was calculated based on accumulative hypergeometric distribution, and the q-value was calculated using the Benjamini-Hochberg program to consider multiple tests ([@b27-ol-0-0-10605]). When hierarchical clustering was performed on enriched terms, the κ score was used as a measure of similarity, and sub-trees with similarity \>0.3 were then treated as clusters.

### Prediction of the lncRNA-miRNA interactions and miRNA-mRNA interactions

The interactions between differentially expressed miRNAs (DEMs) and DEGs were predicted using miRWalk v3.0 (<http://mirwalk.umm.uni-heidelberg.de/>), which integrated the predictions of miRDB ([@b28-ol-0-0-10605]) and TargetScan ([@b29-ol-0-0-10605]). A score ≥0.95 was considered as the critical criterion for miRWalk predictive analysis. Considering the inhibition effect of miRNA on mRNA expression, the interactions of miRNA and mRNA with the same expression tendency were deleted. The interactions between miRNA and lncRNA were predicted using DIANA-LncBase v2.0 ([@b30-ol-0-0-10605]), and the score ≥0.4 was considered to be the cut-off criterion for predictive analysis in the LncBase prediction module. After the predicted targets were intersected with DEGs in the GSE109454 dataset and DEMs in the GSE41655 dataset, the mRNAs, miRNAs and lncRNAs were selected to construct the lncRNA-mRNA-miRNA regulatory network. The cytoscape software (v3.40; <http://cytoscape.org/>) was used to visualize the network.

### Validation in the cancer genome atlas (TCGA) datasets

TCGA is a public platform for researchers to download and assess free datasets (<https://cancergenome.nih.gov/>) ([@b31-ol-0-0-10605]). RNA-sequencing (RNA-seq) data and clinical data from 31 cancer types are included in TCGA. In the present study, to improve the reliability of the analysis, the expression of hub genes was validated in TCGA datasets using an easy-use online tool GEPIA (v1.0; <http://gepia.cancer-pku.cn/>). The tumor type was limited to colon adenocarcinoma (COAD). Finally, RNA-seq data and clinical data from 275 primary tumor samples of COAD and 349 corresponding normal samples in TCGA datasets were used. Box and whisker plots were used to display the expression of the genes involved in the ceRNA network. \|log~2~ FC\|\>1 and P-value \<0.05 were set as the cut-off criteria to determine the differential expression between primary tumor samples and normal samples.

Results
=======

### Identification of DEGs

DEGs in the GSE109454 dataset and DEMs in the GSE41655 dataset were screened with a threshold of P\<0.05 and \|log~2~ FC\|\>1. As shown in [Fig. 1](#f1-ol-0-0-10605){ref-type="fig"}, a total of 2,599 downregulated genes (1,430 mRNAs and 1,169 lncRNAs) and 2,832 upregulated genes (1,753 mRNAs and 1,079 lncRNAs) were screened in the GSE109454 dataset. In the GSE41655 dataset, a total of 116 DEMs, including 71 downregulated miRNAs and 45 upregulated miRNAs, between colorectal adenoma samples and normal colorectal samples, were screened ([Fig. 2A and C](#f2-ol-0-0-10605){ref-type="fig"}), and a total of 109 DEMs, including 55 downregulated miRNAs and 54 upregulated miRNAs, between colorectal adenocarcinoma samples and normal colorectal samples, were screened ([Fig. 2B and D](#f2-ol-0-0-10605){ref-type="fig"}). After the DEMs in the two groups were intersected, 78 DEMs were selected for further analysis.

### Construction of co-expression network

Using the R package for WGCNA, 39 modules were generated ([Fig. 3A](#f3-ol-0-0-10605){ref-type="fig"}) and all of the uncorrelated genes were assigned to the grey module. The number of the genes in every module is shown in [Table III](#tIII-ol-0-0-10605){ref-type="table"}. The trait of the samples in the present study was divided into tumor and non-tumor. Out of 39 modules, the blue module was most positively associated with CRC (r=0.98; P=1×10^−8^; [Fig. 3B](#f3-ol-0-0-10605){ref-type="fig"}). A total of 2,556,690 co-expression relationships in the blue module were therefore further filtered, and 169 genes (86 mRNAs and 83 lncRNAs) and 245 relationships were selected to construct the CNC network ([Fig. 4](#f4-ol-0-0-10605){ref-type="fig"}).

### GO and KEGG pathway enrichment analysis of genes in the CNC network

GO and KEGG enrichment analysis was performed for the genes in the blue module and the result is shown in [Table IV](#tIV-ol-0-0-10605){ref-type="table"}. 'p53 signaling pathway' and 'cell cycle' were the most significantly enriched pathways in the KEGG pathway enrichment analysis. 'Cell division', 'chromosome segregation' and 'mitotic nuclear division' were the top 3 enriched BP terms.

### Construction and validation of ceRNA network

To identify how lncRNAs regulate mRNAs through miRNAs in the CNC network, online prediction tools were used to determine miRNA-lncRNA and miRNA-mRNA interactions. The predicted miRNAs were then intersected with DEMs identified in the GSE41655 dataset. Subsequently a ceRNA network was constructed, which was composed of 24 mRNAs, 16 miRNAs and 10 lncRNAs ([Fig. 5](#f5-ol-0-0-10605){ref-type="fig"}). To improve the reliability of the analysis, the expression of genes involved in the ceRNA network was validated in TCGA datasets. The results showed that 3 lncRNAs (MIR22HG, CHL1-AS2 and RP11-61I13.3) were downregulated in TCGA datasets ([Fig. 6](#f6-ol-0-0-10605){ref-type="fig"}). As shown in [Fig. 7](#f7-ol-0-0-10605){ref-type="fig"}, ANK2, BTK, FGL2, GBP2, PCSK5 and PDK4 were downregulated, and ARMC10, CENPF, CENPF, DKC1, GINS4, PAICS, PARPBP, RAD54B, RAE1 and TOMM34 were upregulated in TCGA datasets. Subsequently, these validated mRNAs and lncRNAs were selected to construct a ceRNA network. Finally, a validated ceRNA network composed of 2 lncRNAs (MIR22HG and RP11-61I13.3), 5 miRNAs (hsa-miR-765, hsa-miR-198, hsa-miR-125a-3p, hsa-miR-149-3p and hsa-miR-650) and 5 mRNAs (ANK2, BTK, GBP2, PCSK5 and PDK4) was obtained ([Fig. 8](#f8-ol-0-0-10605){ref-type="fig"}). PCSK5 was at the center of the validated ceRNA network, and interacted with 4 miRNAs.

Discussion
==========

In developing countries, the incidence of CRC is rapidly increasing. CRC is the fifth most common malignant tumor after lung, liver, esophagus and breast cancer in China ([@b32-ol-0-0-10605]). Statistically, there were 376,300 new cases and 191,000 CRC-related deaths in China in 2015 ([@b32-ol-0-0-10605]). Therefore, CRC has become a public health issue and it is essential to understand the etiological factors and mechanisms of CRC progression to improve prevention and survival rates.

In the present study, 3,183 dysregulated mRNAs, 78 dysregulated miRNAs and 2,248 dysregulated lncRNAs were screened in two GEO datasets. WGCNA analysis was conducted to identify the co-expression between coding genes and non-coding genes. Combined with the dysregulated genes, 169 genes were selected to construct the CNC network. GO and KEGG pathway enrichment analysis was performed to identify the biological function of the genes in the CNC network. The genes in the CNC network were significantly enriched in 'cell cycle' and 'p53 signaling pathway'. DEMs identified from the GS41655 dataset were predicted to be involved in miRNA-lncRNA and miRNA-mRNA interactions were used to construct the ceRNA network. The expression of 3 lncRNAs (MIR22HG, CHL1-AS2 and RP11-61I13.3) and 15 mRNAs (ANK2, ARMC10, BTK, CENPF, DKC1, FGL2, GBP2, GINS4, PAICS, PARPBP, PCSK5, PDK4, RAD54B, RAE1 and TOMM34) in the ceRNA network were validated and found to be dysregulated in TCGA datasets.

PCSK5 is at the center of the validated ceRNA network, and interacts with 4 miRNAs. PCSK5 belongs to the subtilisin-like proprotein convertase family. The members of this family are proprotein convertases that process a potential precursor protein into its biologically active product ([@b33-ol-0-0-10605]). Reports of the involvement of PCSK5 in cancer are rare. In triple-negative breast cancer (TNBC), a lack of PCSK5 could lead to the bioactivity of growth differentiation factor (GDF11) as a tumor-suppressor. PCSK5 reconstitution mobilizes the latent TNBC reservoir of GDF11 *in vitro* and inhibits TNBC metastasis to the lung of syngeneic hosts ([@b34-ol-0-0-10605]). However, the function of PCSK5 in CRC is largely unknown. The present study indicated that PCSK5 could be regulated by MIR22HG through miR-198 and miR-149-3p, and regulated by RP11-61I13.3 through miR-765 and miR-125-3p.

MIR22HG has been identified as a tumor suppressor in several studies. In hepatocellular carcinoma (HCC), MIR22HG expression is significantly downregulated, and can regulate the expression of high mobility group box 1 and its downstream pathways by deriving miR-22-3p to suppress HCC cell proliferation, invasion and metastasis ([@b35-ol-0-0-10605]). In endometrial cancer (EC), MIR22HG can act as sponge of miR-141-3p, which could inhibit EC cells proliferation and induce EC cells apoptosis by targeting death-associated protein kinase 1 ([@b36-ol-0-0-10605]). In addition, the present study suggested that MIR22HG could regulate the expression of BTK and PDK4 through miR-650. Therefore, MIR22HG might be an important regulator in CRC. BTK is a new regulator of p53 and BTK induction, which leads to p53 phosphorylation. Inhibiting BTK can reduce p53-dependent senescence and apoptosis ([@b37-ol-0-0-10605]). In CRC, miR-650 is a direct regulator of N-myc downstream-regulated gene 2, which is a potential tumor suppressor gene ([@b38-ol-0-0-10605]). Therefore, MIR22HG might be an important regulator in CRC.

RP11-61I13.3 is a novel lncRNA and little is known about its function. RP11-61I13.3 can also regulate GBP2 and ANK2 through miR-765, and miR-765 has been demonstrated to be an onco-miRNA in HCC ([@b39-ol-0-0-10605]) and oral squamous cancer ([@b40-ol-0-0-10605]). Meanwhile, GBP2 has been associated with a better prognosis in several cancer types, including breast cancer and ovarian cancer ([@b41-ol-0-0-10605],[@b42-ol-0-0-10605]).

In conclusion, two lncRNAs (MIR22HG and RP11-61I13.3) have been identified that can regulate several mRNAs through sponging miRNAs in CRC, and the potential functions of these genes have been revealed. The ceRNA network involved in PCSK5 has been shown to play an important role in CRC. However, the diagnostic and prognostic value of these genes still requires further validation.
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![Identification of differentially expressed genes between tumor and normal samples in the GSE109454 dataset. (A) The volcano plot. The green dots indicate the significantly downregulated genes, the red dots indicate the significantly upregulated genes, while the blue dots indicate the genes with no significant difference. The horizontal axis represents the log~2~ (fold change) and the vertical axis represents the -log~10~ (P-value). (B and C) Heatmaps of the (B) differentially expressed mRNAs and (C) differentially expressed lncRNAs. Each row presents a dysregulated RNA transcript and each column represents a sample. Orange represents upregulation and blue represents downregulation.](ol-18-03-3137-g00){#f1-ol-0-0-10605}

![Identification of DEMs between tumor and normal samples in the GSE41655 dataset. (A) The volcano plots of the DEMs between colorectal adenoma samples and normal colorectal samples. (B) The volcano plots of the DEMs between colorectal adenocarcinoma samples and normal colorectal samples. The green dots indicate the significantly downregulated genes, the red dots indicate the significantly upregulated genes and the blue dots indicate the genes with no significant difference. The horizontal axis represents the log~2~ (fold change) and the vertical axis represents the -log~10~ (P-value). (C) Heatmaps of DEMs between colorectal adenoma samples and normal colorectal samples. (D) Heatmaps of DEMs between colorectal adenocarcinoma samples and normal colorectal samples. Each row presents a dysregulated RNA transcript and each column represents a sample. Orange represents upregulation and blue represents downregulation. DEMs, differentially expressed mRNAs.](ol-18-03-3137-g01){#f2-ol-0-0-10605}

![(A) Hierarchical clustering dendrogram of all the probe sets used in the weighted gene co-expression network analysis based on the 1-TOM dissimilarity measure. Each line of the dendrogram represents an individual probe. The multi-color bar represents the 39 modules identified using the dynamic tree cut algorithm. (B) Correlations between module eigengenes and tumor status. The numbers within the heatmap indicate correlations and P-values for the module-trait associations, respectively. Red wells indicate positive correlation, blue wells indicate negative correlation and white wells indicate no correlation.](ol-18-03-3137-g02){#f3-ol-0-0-10605}

![Coding non-coding network. Red represents upregulation and blue represents downregulation. The V-shape represents lncRNA and circles represent mRNA.](ol-18-03-3137-g03){#f4-ol-0-0-10605}

![Competing endogenous RNA network. Red represents upregulation and blue represents downregulation. The V-shape represents lncRNA, circles represent mRNA and triangles represent microRNA.](ol-18-03-3137-g04){#f5-ol-0-0-10605}

![Gene expression of the selected long non-coding RNAs validated in The Cancer Genome Atlas dataset. The dysregulation of (A) MIR22HG, (B) CHL1-AS2 and (C) RP11-61I13.3. The red box corresponds to tumor samples and the grey box corresponds to non-tumor samples. The vertical axis represents the relative expression of genes. \*P\<0.05. COAD, colon adenocarcinoma; T, tumor; N, normal.](ol-18-03-3137-g05){#f6-ol-0-0-10605}

![Gene expression of the selected mRNAs validated in The Cancer Genome Atlas dataset. The dysregulation of (A) ANK2, (B) ARMC10, (C) BTK, (D) CENPF, (E) DKC1, (F) FGL2, (G) GBP2, (H) GINS4, (I) PAICS, (J) PARPBP, (K) PCSK5, (L) PDK4, (M) RAD54B, (N) RAE1 and (O) TOMM34. The red box corresponds to tumor samples and the grey box corresponds to non-tumor samples. The vertical axis represents the relative expression of genes. \*P\<0.05. COAD, colon adenocarcinoma; T, tumor; N, normal.](ol-18-03-3137-g06){#f7-ol-0-0-10605}

![Competing endogenous RNA network constructed from validated genes. Red represents upregulation and blue represents downregulation. V-shape represents lncRNA, circle represents mRNA, and triangle represents miRNA.](ol-18-03-3137-g07){#f8-ol-0-0-10605}

###### 

Clinical information of the patients included in the GSE109454 dataset ([@b18-ol-0-0-10605]).

  Sex      Age, years   TNM stage ([@b22-ol-0-0-10605])   CEA, ng/ml
  -------- ------------ --------------------------------- ------------
  Male     55           II                                12.43
  Male     61           IVA                               37.84
  Female   56           IIIB                              23.60
  Male     59           IIIA                              39.93
  Female   53           II                                15.51
  Female   63           IIIA                              18.89

CEA, carcinoembryonic antigen; TNM, Tumor-Node-Metastasis.

###### 

Clinical information of the patients included in the GSE41655 dataset (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE41655>).

  Sex      Age, years   Pathological grade ([@b21-ol-0-0-10605])   pTNM stage ([@b22-ol-0-0-10605])
  -------- ------------ ------------------------------------------ ----------------------------------
  Male     35           Normal epithelium                          
  Male     60           Normal epithelium                          
  Male     53           Normal epithelium                          
  Male     68           Normal epithelium                          
  Female   61           Normal epithelium                          
  Female   55           Normal epithelium                          
  Male     29           Normal epithelium                          
  Male     37           Normal epithelium                          
  Female   38           Normal epithelium                          
  Female   22           Normal epithelium                          
  Female   62           Normal epithelium                          
  Male     69           Normal epithelium                          
  Female   46           Normal epithelium                          
  Male     51           Normal epithelium                          
  Female   39           Normal epithelium                          
  Male     49           Low-grade dysplasia                        
  Female   51           Low-grade dysplasia                        
  Male     64           High-grade dysplasia                       
  Male     69           Low-grade dysplasia                        
  Male     54           Low-grade dysplasia                        
  Male     60           Low-grade dysplasia                        
  Male     61           Low-grade dysplasia                        
  Female   74           Low-grade dysplasia                        
  Male     64           Low-grade dysplasia                        
  Male     61           High-grade dysplasia                       
  Female   70           High-grade dysplasia                       
  Male     83           High-grade dysplasia                       
  Female   53           High-grade dysplasia                       
  Male     49           High-grade dysplasia                       
  Female   29           High-grade dysplasia                       
  Male     49           High-grade dysplasia                       
  Female   70           High-grade dysplasia                       
  Male     80           High-grade dysplasia                       
  Male     65           High-grade dysplasia                       
  Male     56           High-grade dysplasia                       
  Female   76           High-grade dysplasia                       
  Male     56           High-grade dysplasia                       
  Male     74           High-grade dysplasia                       
  Male     61           High-grade dysplasia                       
  Male     35           Low-grade dysplasia                        
  Male     59           Low-grade dysplasia                        
  Female   53           High-grade dysplasia                       
  Female   68           Low-grade dysplasia                        
  Male     61           Low-grade dysplasia                        
  Female   43           Low-grade dysplasia                        
  Male     37           Low-grade dysplasia                        
  Male     55           High-grade dysplasia                       
  Male     82           High-grade dysplasia                       
  Female   62           Low-grade dysplasia                        
  Male     72           Low-grade dysplasia                        
  Male     62           Low-grade dysplasia                        
  Female   34           Low-grade dysplasia                        
  Female   61           Low-grade dysplasia                        
  Female   58           Low-grade dysplasia                        
  Female   53           Low-grade dysplasia                        
  Male     76           Low-grade dysplasia                        
  Male     29           Low-grade dysplasia                        
  Male     37           Low-grade dysplasia                        
  Male     38           Low-grade dysplasia                        
  Female   22           Low-grade dysplasia                        
  Male     69           Low-grade dysplasia                        
  Male     69           Low-grade dysplasia                        
  Male     65           Low-grade dysplasia                        
  Male     49           High-grade dysplasia                       
  Male     69           Low-grade dysplasia                        
  Male     63           Low-grade dysplasia                        
  Male     57           Low-grade dysplasia                        
  Female   56           Low-grade dysplasia                        
  Female   69           Low-grade dysplasia                        
  Female   72           Low-grade dysplasia                        
  Female   65           Low-grade dysplasia                        
  Male     75           Low-grade dysplasia                        
  Male     57           Low-grade dysplasia                        
  Female   35           Low-grade dysplasia                        
  Male     69           Adenocarcinoma                             T2N0M0
  Male     63           Adenocarcinoma                             T4N1M1
  Male     64           Adenocarcinoma                             T3N1M0
  Female   75           Adenocarcinoma                             T1N0M0
  Male     49           Adenocarcinoma                             T3N1M0
  Female   70           Adenocarcinoma                             T3N1M0
  Male     80           Adenocarcinoma                             T1N0M0
  Male     65           Adenocarcinoma                             T2N0M0
  Male     56           Adenocarcinoma                             T3N0M0
  Female   76           Adenocarcinoma                             T2N1M0
  Male     56           Adenocarcinoma                             T1N0M0
  Female   68           Adenocarcinoma                             T2N1M0
  Male     74           Adenocarcinoma                             T4N1M0
  Male     61           Adenocarcinoma                             T4N1M0
  Male     70           Adenocarcinoma                             T3N1M0
  Female   80           Adenocarcinoma                             T1N0M0
  Male     71           Adenocarcinoma                             T2N0M0
  Male     35           Adenocarcinoma                             T3N0M0
  Male     59           Adenocarcinoma                             T3N0M0
  Male     60           Adenocarcinoma                             T3N0M0
  Female   68           Adenocarcinoma                             T2N0M0
  Male     61           Adenocarcinoma                             T3N1M0
  Male     51           Adenocarcinoma                             T3N1M0
  Male     55           Adenocarcinoma                             T4N2M1
  Male     66           Adenocarcinoma                             T3N1M0
  Male     72           Adenocarcinoma                             T4N2M0
  Female   34           Adenocarcinoma                             T4N2M0
  Female   63           Adenocarcinoma                             T1N0M0
  Male     63           Adenocarcinoma                             T1N0M0
  Male     69           Adenocarcinoma                             T4N1M0
  Female   69           Adenocarcinoma                             T2N0M0
  Male     61           Adenocarcinoma                             T4N1M0
  Male     45           Adenocarcinoma                             T2N0M0

pTNM, pathological Tumor-Node-Metastasis.

###### 

Number of genes in the 39 modules.

  Module colors      Frequency
  ------------------ -----------
  Black              426
  Blue               2,249
  Brown              1,417
  Cyan               274
  Dark green         133
  Dark grey          103
  Dark magenta       56
  Dark olive green   59
  Dark orange        84
  Dark red           145
  Dark turquoise     103
  Green              507
  Green yellow       293
  Grey               191
  Grey 60            223
  Light cyan         246
  Light green        177
  Light yellow       169
  Magenta            349
  Midnight blue      264
  Orange             97
  Pale turquoise     60
  Pink               391
  Plum 1             39
  Purple             313
  Red                439
  Royal blue         154
  Saddle brown       63
  Salmon             282
  Sienna 3           52
  Sky blue           72
  Sky blue 3         47
  Steel blue         63
  Tan                291
  Turquoise          3,809
  Violet             59
  White              80
  Yellow             909
  Yellow green       48

###### 

Gene function enrichment analysis of the genes included in the coding non-coding network.

  Category   Term                                                                                                               Count   P-value       Genes
  ---------- ------------------------------------------------------------------------------------------------------------------ ------- ------------- ------------------------------------------------------------------------------------
  KEGG       Cell cycle                                                                                                           5     1.66×10^−3^   CDK1, MAD2L1, CCNB2, E2F5, ATR
             p53 signaling pathway                                                                                                3     3.18×10^−2^   CDK1, CCNB2, ATR
  BP         Cell division                                                                                                      13      7.04×10^−8^   CDK1, MAD2L1, CCNB2, KIF11, OIP5, NEK2, KIF20B, NUF2, SDCCAG3, CENPF, AURKA, UBE2C
             Mitotic nuclear division                                                                                           10      2.17×10^−6^   CDK1, KIF11, CCNB2, OIP5, NEK2, KIF20B, NUF2, CENPF, CENPW, AURKA
             Chromosome segregation                                                                                               6     1.58×10^−5^   KIF11, OIP5, NEK2, NUF2, CENPF, CENPW
             DNA strand elongation involved in DNA replication                                                                    4     4.21×10^−5^   GINS1, RFC3, GINS4, POLD2
             Positive regulation of telomere maintenance via telomerase                                                           4     4.34×10^−4^   DKC1, NEK2, ATR, CCT6A
             DNA replication                                                                                                      6     7.71×10^−4^   CDK1, RFC3, GINS4, POLD2, ATR, DSCC1
             DNA repair                                                                                                           7     7.81×10^−4^   CDK1, RAD51AP1, FANCD2, PARPBP, RUVBL2, ACTL6A, ATR
             CENP-A containing nucleosome assembly                                                                                4     1.04×10^−3^   CENPL, OIP5, CENPQ, CENPW
             DNA duplex unwinding                                                                                                 4     1.11×10^−3^   GINS1, GINS4, RUVBL2, RAD54B
             Sister chromatid cohesion                                                                                            5     1.35×10^−3^   CENPL, MAD2L1, CENPQ, NUF2, CENPF
             Positive regulation of telomerase RNA localization to Cajal body                                                     3     2.15×10^−3^   DKC1, RUVBL2, CCT6A
             Spindle organization                                                                                                 3     2.45×10^−3^   KIF11, AURKA, AUNIP
             Cell cycle                                                                                                           6     3.38×10^−3^   DTYMK, SDCCAG3, AURKA, ATR, CDKN3, SUV39H2
             G2/M transition of mitotic cell cycle                                                                                5     3.79×10^−3^   CDK1, PLK4, CCNB2, NEK2, AURKA
             Regulation of mitotic nuclear division                                                                               3     5.50×10^−3^   MKI67, NEK2, KIF20B
             Anaphase-promoting complex-dependent catabolic process                                                               4     5.92×10^−3^   CDK1, MAD2L1, AURKA, UBE2C
             Cytoplasmic translation                                                                                              3     5.96×10^−3^   RPL6, RPL8, FTSJ1
             Reciprocal meiotic recombination                                                                                     3     8.52×10^−3^   CCNB1IP1, RAD54B, TRIP13
             Histone H4 acetylation                                                                                               3     9.08×10^−3^   NCOA1, RUVBL2, ACTL6A
             Positive regulation of type I hypersensitivity                                                                       2     01.3871       FCER1A, BTK
             Mitotic nuclear envelope disassembly                                                                                 3     1.78×10^−2^   CDK1, CCNB2, RAE1
             Regulation of mitotic centrosome separation                                                                          2     1.85×10^−2^   KIF11, NEK2
             Interstrand cross-link repair                                                                                        3     2.18×10^−2^   RAD51AP1, FANCD2, ATR
             Mitotic centrosome separation                                                                                        2     2.30×10^−2^   KIF11, AURKA
             Regulation of growth                                                                                                 3     2.52×10^−2^   ARMC10, RUVBL2, ACTL6A
             Cell proliferation                                                                                                   6     2.77×10^−2^   CDK1, MKI67, DKC1, DLGAP5, DTYMK, CENPF
             Positive regulation of DNA-directed DNA polymerase activity                                                          2     3.21×10^−2^   RFC3, DSCC1
             Box C/D snoRNP assembly                                                                                              2     3.21×10^−2^   NUFIP1, RUVBL2
             Protein ubiquitination involved in ubiquitin-dependent protein catabolic process                                     4     3.44×10^−2^   CDK1, MAD2L1, AURKA, UBE2C
             Positive regulation of establishment of protein localization to telomere                                             2     4.10×10^−2^   DKC1, CCT6A
             Negative regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle                              3     4.31×10^−2^   CDK1, MAD2L1, UBE2C
             Positive regulation of ubiquitin-protein ligase activity involved in regulation of mitotic cell cycle transition     3     4.87×10^−2^   CDK1, MAD2L1, UBE2C

[^1]: Contributed equally
